Peptide / Metabolic

Survodutide (BI 456906)

Dual glucagon/GLP-1 receptor co-agonist. The glucagon component drives significantly greater fat oxidation than GLP-1 alone — particularly effective for hepatic fat reduction (NASH/MAFLD). Phase 2 data shows superior weight loss and liver fat reduction vs semaglutide. Once-weekly injection.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose0.3–4.8 mg SubQ once weekly (titration protocol)

Half-life168 hours

Risk flagmoderate

Regulatory noteResearch-only flag

Side effects and watch-outs

Nausea and vomiting (dose-limiting on titration)
Diarrhoea
Decreased appetite
Hepatic enzyme elevation (monitor ALT/AST)
Injection site reaction
⚠️ Tachycardia — glucagon receptor activation increases heart rate
Headache
Fatigue